When should antiretroviral therapy be started for HIV-infected infants in resource-limited settings?

Future HIV Therapy

Volumn 2, Issue 3, 2008, Pages 201-208

  Prendergast, Andrew ^a   Cottorr, Mark ^b,c   Gibb, Diana M ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Faculty of Health Sciences   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAIN DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEVELOPMENTAL DISORDER; DISEASE COURSE; DISEASE TRANSMISSION; DRUG DOSE TITRATION; EARLY DIAGNOSIS; EDITORIAL; GROWTH DISORDER; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION PREVENTION; MONOTHERAPY; MORTALITY; PERINATAL CARE; PRACTICE GUIDELINE; SINGLE DRUG DOSE;

EID: 52349098772     PISSN: 17469600     EISSN: None     Source Type: Journal    
DOI: 10.2217/17469600.2.3.201     Document Type: Editorial

References (36)

1. European Collaborative Study: Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 40(3), 458-465 (2005).
2. Havens PL, Gibb DM: Increasing antiretroviral Drug access for children with HIV infection. Pediatrics 119(4), 838-845 (2007).
3. Kline M: Perspectives on the pediatric HIV pandemic: catalyzing access of children to care and treatment. Pediatrics 117(4), 1388-1393 (2006).
4. Owens DK, Holodniy M, McDonald TW, Scott J, Sonnad S: A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants. JAMA 275(17), 1342-1348 (1996).
5. McIntosh K, Shevitz A, Zaknun D et al.: Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr. Infect. Dis. J. 15(12), 1087-1091 (1996).
6. Mphatswe W, Blanckenberg N, Tudor-Williams G et al.: High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS 21(10), 1253-1261 (2007).
7. Obimbo EM, Mbori-Ngacha DA, Ochieng JO et al.: Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected African children. Pediatr. Infect. Dis. J. 23(6), 536-543 (2004).
8. Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 362(9396), 1605-1611 (2003).
9. Kekitiinwa A, Lee K, Walker A et al.: Initial growth, CD4 and viral load responses to HAART in Ugandan compared to UK/Irish HIV-infected children. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, USA, 3-6 February 2008 (Abstract 584).
10. Dabis F, Elenga N, Meda N et al.: 18-month mortality and perinatal exposure to zidovudine in West Africa. AIDS 15 (6), 771-779 (2001).
11. Gibb DM, Duong T, Tookey PA et al.: Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. Br. Med. J. 327 (7422), 1019 (2003).
12. Gortmaker SL, Hughes M, Cervia J et al.: Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N. Engl. J. Med. 345(21), 1522-1528 (2001).
13. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM: PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med. 5(Suppl. 2), 61-86 (2004).
14. Dunn D, Woodburn P, Duong T et al.: Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J. Infect. Dis. 197(3), 398-404 (2008).
15. Berk DR, Falkovitz-Halpern MS, Hill DW et al.: Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA 293(18), 2221-2231 (2005).
16. Berk DR, Falkovitz-Halpern MS, Sullivan B, Ruiz J, Maldonado YA: Disease progression among HIV-infected children who receive perinatal zidovudine prophylaxis. J. Acquir. Immune Defic. Syndr. 44(1). 106-111 (2007).
17. Faye A, Le Chenadec J, Dollfus C et al.: Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin. Infect. Dis. 39(11), 1692-1698 (2004).
18. Goetghebuer T, Haelterman E, Le Chenadec J et al.: Early verus deferred highly active antiretroviral therapy in HIV infected infants: a European Collaborative Cohort Study. Presented at: 4th Dominique Dormont International Conference: Host-Pathogen Interactions in Chronic Infections. Paris, France, 13-15 December 2007 (Abstract 025).
19. Violari A, Cotton M, Gibb D, et al. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. Presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, 22-25 July 2007 (Abstract WESS103).
20. Emery S, SMART Study Group and INSIGHT: Major clinical outcomes in patients not treated with antiretroviral therapy (ART) at baseline in SMART; a rationale for a trial to examine early treatment of HIV disease. Presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, 22-25 July 2007.
21. Aboulker JP, Babiker A, Chaix ML et al.: Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 18(2), 237-245 (2004).
22. Doerholt K, Duong T, Tookey P et al.: Outcomes for human imnmunodeficiency virus-1-infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr. Infect. Dis. J. 25, 420-426 (2006).
23. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL: A trial of, three antiretroviral regimens in HIV-1-infected children. N. Engl. J. Med. 350(24), 2471-2480 (2004).
24. Walker AS, Doerholt K, Sharland M, Gibb DM: Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 18(14), 1915-1924 (2004).
25. Judd A, Doerholt K, Tookey PA et al.: Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin. Infect. Dis. 45(7), 918-924 (2007).
26. Chiappini E, Galli L, Zazzi M, de Martino M: Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active, antiretroviral therapy. J. Med. Virol. 70(4), 506-512 (2003).
27. Rabkin M, El-Sadr W, Katzenstein DA et al.: Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet 360(9344), 1503-1505 (2002).
28. Smith K, Kuhn L, Coovadia A et al.: Immune reconstitution inflammatory syndrome in infants and young children initiating ART. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, USA, 3-6 February 2008 (Abstract 75).
29. No authors listed. Weight, height and human immunodeficiency virus infection in young children of infected mothers. The European Collaborative Study. Pediatr. Infect. Dis. J. 14(8), 685-690 (1995).
30. Prendergast A, Mphatswe W, Tudor-Williams G et al.: Early virological - suppression despite high frequency NNRTI resistance following perinatal prophylaxis in HIV-infected African infants. Presented at: 4th Dominique Dormont International Conference. Paris, France, 13-15 December 2007 (Abstract 027).
31. Lockman S, Shapiro RL, Smeaton LM et al.: Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med. 356(2), 135-147 (2007).
32. Barlow-Mosha L, Ajunua P, Mubiru M et al.: Early Effectiveness of a NVP-based HAART regimen among HIV-infected children with and without prior single-dose NVP exposure. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, USA, 3-6 February 2008 (Abstract 583).
33. Chi BH, Chintu N, Lee A, Stringer EM, Sinkala M, Stringer JS: Expanded services for the prevention of mother-to-child HIV transmission: field acceptability of a pilot program in Lusaka, Zambia. J. Acquir. Immune Defic. Syndr. 45(1), 125-127 (2007).
34. Moses A, Zimba C, Kamanga E et al.: Prevention of mother-to-child transmission: program changes and the effect on uptake of the HIVNET 012 regimen in Malawi. AIDS 22(1), 83-87 (2008).
35. Ginsburg AS, Hoblitzelle CW, Sripipatana TL, Wilfert CM: Provision of care following prevention of mother-to-child HIV transmission services in resource-limited settings. AIDS21(18), 2529-2532 (2007).
36. Prendergast A, Chonco F, Tudor-Williams G et al.: Randomized, controlled trial of 3 approaches to management of HIV-infected infants. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, USA, 3-6 February 2008 (Abstract 77LB).